Interstitial and Parenchymal Lung Disease
Interstitial and parenchymal lung diseases are a broad family of disorders that injure the lung interstitium and alveolar structures rather than the airways, producing inflammation, fibrosis, or both. They share a clinical pattern of progressive breathlessness, restrictive physiology, and diffuse changes on imaging, but differ widely in cause, course, and prognosis.
Definition
Interstitial lung disease (ILD), also called diffuse parenchymal lung disease, denotes a heterogeneous group of conditions characterized by diffuse involvement of the lung interstitium and alveolar walls, often leading to restrictive pulmonary physiology and impaired gas exchange.
Scope
This area orients the reader to the group of diffuse parenchymal lung diseases, the way they are classified, and the shared diagnostic logic that distinguishes them. It links to detailed topic entries on idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and sarcoidosis. It is a reference overview of a disease group, not a clinical management guide.
Sub-topics
Key concepts
- Lung interstitium and alveolar wall
- Restrictive pulmonary physiology
- Diffuse parenchymal involvement
- Idiopathic interstitial pneumonias
- Fibrotic versus inflammatory ILD
- Multidisciplinary diagnosis
- High-resolution computed tomography (HRCT) patterns
- Progressive pulmonary fibrosis phenotype
Mechanisms
ILDs converge on injury to the alveolar-interstitial compartment. In some, the dominant process is inflammation of the alveolar walls (alveolitis); in others, repeated epithelial injury and dysregulated repair drive deposition of extracellular matrix and progressive fibrosis. The resulting thickening and distortion of the interstitium reduces lung compliance (restriction) and impairs diffusion of gases across the alveolar-capillary membrane. Because many different exposures, immune processes, and idiopathic mechanisms can produce overlapping patterns, diagnosis rests on integrating clinical, radiologic, and where needed pathologic information.
Clinical relevance
The ILD family is clinically important because its members range from self-limited or treatment-responsive inflammatory disease to relentlessly progressive fibrosis, and distinguishing them shapes prognosis and surveillance. This entry describes how the group is conceptualized and classified for reference and education; it does not provide diagnostic criteria or treatment recommendations for individual patients.
Epidemiology
Collectively ILDs are uncommon relative to airway diseases, but they account for substantial respiratory morbidity and mortality. Idiopathic pulmonary fibrosis is among the most studied and carries one of the poorest prognoses, while a subset of fibrotic ILDs of various causes can follow a progressive-fibrosing course resembling it.
History
Modern understanding of the interstitial pneumonias was shaped by successive international classifications that separated clinically and pathologically distinct entities. The American Thoracic Society/European Respiratory Society multidisciplinary classification, updated in 2013, organized the idiopathic interstitial pneumonias and established the multidisciplinary discussion as the reference standard for diagnosis.
Related topics
Seminal works
- travis-2013-atsers
- lederer-2018
Frequently asked questions
- What distinguishes interstitial lung disease from airway diseases like asthma or COPD?
- ILDs primarily affect the lung interstitium and alveolar walls, typically producing restrictive physiology and impaired gas diffusion, whereas asthma and COPD primarily affect the airways and produce obstructive physiology.
- Are all interstitial lung diseases progressive and irreversible?
- No. The group ranges from inflammatory forms that may stabilize or improve to fibrotic forms that progress; the course depends on the specific diagnosis, which is why classification matters.